IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
IMMUNOTECH-B: FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON 24 MAY 2024
IMMUNOTECH-B: NOTICE OF ANNUAL GENERAL MEETING
IMMUNOTECH-B: PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE FOURTH MEMORANDUM AND ARTICLES OF ASSOCI
IMMUNOTECH-B: 2023 ANNUAL REPORT
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
IMMUNOTECH-B: PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE FOURTH MEMORANDUM AND ARTICLES OF ASSOCIATION
IMMUNOTECH-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
IMMUNOTECH-B: DATE OF BOARD MEETING
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
IMMUNOTECH-B: VOLUNTARY ANNOUNCEMENT THE CLINICAL TRIAL APPROVAL FOR THE aT19 INJECTION
IMMUNOTECH-B: Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
IMMUNOTECH-B: Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
IMMUNOTECH-B: VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE PHASE II CLINICAL TRIAL FOR CAR-T-19 INJECTION
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
IMMUNOTECH-B: VOLUNTARY ANNOUNCEMENT RECEIPT OF THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE aT19 INJECTION
IMMUNOTECH-B: VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE PHASE I CLINICAL TRIAL FOR THE DENOCABTAGENE CILOLEUCEL INJECTION
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
No Data